Evidence map›Paper›PMID 42626720›Full record

ArticleRheumatology advances in practice2026

Incidence and prevalence of Takayasu arteritis in England before and after the COVID-19 pandemic: results from RECORDER.

Stephanie J Lax, Mehrdad A Mizani, Megan Rutter, David Groves, Peter Lanyon, Matthew J Grainge, Sean McPhail, Peter Stilwell, Jeanette Aston, Mary Bythell and 7 more

Abstract read
In one paragraph

Article in Rheumatology advances in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Stephanie J LaxDepartment of Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0002-7000-9364
Mehrdad A MizaniBritish Heart Foundation Data Science Centre, Health Data Research UK, London, UK.ORCID https://orcid.org/0000-0002-2441-895X
Megan RutterDepartment of Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0002-1522-9620
David GrovesDepartment of Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0001-7810-7391
Peter LanyonDepartment of Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0002-9855-6802
Matthew J GraingeDepartment of Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0001-7181-4042
Sean McPhailNational Disease Registration Service, NHS England, Leeds, UK.
Peter StilwellNational Disease Registration Service, NHS England, Leeds, UK.ORCID https://orcid.org/0000-0002-4169-4200
Jeanette AstonNational Disease Registration Service, NHS England, Leeds, UK.
Mary BythellNational Disease Registration Service, NHS England, Leeds, UK.ORCID https://orcid.org/0000-0003-1299-1297
Andrew PorterNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0002-2302-3235
Robert T MaughanNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0003-4153-903X
Taryn YoungsteinNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0002-8297-556X
Justin C MasonNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-7783-1660
Fiona A PearceDepartment of Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK.ORCID https://orcid.org/0000-0003-2884-1998
CVD-COVID-UK/COVID-IMPACT Consortium
CVD-COVID-UK/COVID-IMPACT Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Takayasu arteritis (TAK) is a rare large vessel vasculitis associated with substantial morbidity and mortality. Evidence on its epidemiology, including the COVID-19 pandemic's impacts, is incomplete. We aimed to describe the incidence and prevalence of TAK in England using national routinely collected healthcare data. Methods: Using Hospital Episode Statistics for the whole of England (Admitted Patient Care and Outpatients), we identified all people with the International Classification of Diseases, 10th revision code for TAK. We validated our case ascertainment and diagnosis date refinement strategies in five National Health Service Trusts and using the unique Imperial College TAK cohort of 123 confirmed cases. We calculated the incidence of TAK in England from 2006 to 2023 (cohort design), particularly focusing on the COVID-19 pandemic, and point prevalence for 1 July 2022 (cross-sectional design). Results were reported by key demographic variables. Results: The incidence of TAK in England was 1.3 (95% CI 1.3, 1.4) per million per year and was stable except for a 30% decrease in 2020-2021 (COVID-19 pandemic). The prevalence of TAK in mid-2022 was 22.5 per million (95% CI 21.3, 23.8). The median age at diagnosis was 53 years. Incidence and prevalence were both higher in women and in Asian/Asian British and Other ethnic groups. There was variation between different geographic areas, but socio-economic status did not have a marked effect. Conclusion: Nearly 1300 people have TAK in England, with >70 new cases each year apart from during the COVID-19 pandemic. These estimates, based on a 10-fold larger cohort than previous European studies, will be essential in planning and commissioning pandemic-prepared specialist services.

Indexed as

COVID-19epidemiologyincidenceprevalenceTakayasu arteritis

Identifiers

PMID42626720
PMCPMC13493044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.